Integrated early-phase hVIVO offers a unified early‑phase ecosystem combining clinical sites, virology and immunology labs, human challenge expertise, and development consulting. This positions the company to upsell sponsors seeking faster, decision‑ready Phase I/II data and a single vendor for end‑to‑end early development.

Scaleable capacity With the largest purpose‑built human challenge units in London and additional capacity in Germany, hVIVO can accommodate multiple concurrent studies and expand throughput for sponsors facing tight timelines and high patient recruitment needs.

Respiratory and beyond Strong focus on respiratory and infectious diseases, with growing capabilities in cardiometabolic and other high‑growth areas. This creates cross‑sell opportunities into sponsors expanding therapeutic pipelines or seeking expertise across multiple modalities.

Client footprint Serving seven of the world’s ten largest biopharma companies indicates a validated value proposition and potential for deeper collaborations, strategic programs, and multi‑study contracts with established industry leaders.

Data and speed advantage Integrated services enable rapid generation of rigorous human data and continuous patient recruitment through FluCamp, offering a compelling value proposition for sponsors prioritizing faster decision making and reduced development uncertainty in early trials.